BibTex RIS Kaynak Göster

A different insight into blood coagulation in vitro

Yıl 2010, Cilt: 1 Sayı: 3, 173 - 176, 01.09.2010
https://doi.org/10.5799/ahinjs.01.2010.03.0036

Öz

Objectives: The known model of blood coagulation involves a series of zymogen activation reaction sequences. At each stage, a zymogen is converted to an active protease by cleavage of one or more peptide bonds in the precursor molecule. The aim of this study was to investigate amino acid profiles during coagulation process in different conditions in vitro. Methods: Samples of serum and plasma (treated by EDTA or citrate) were obtained from healthy donors and from patients with Phenylketonuria (PKU). Amino acid profiles analyzed with reverse phase HPLC column. Results: There were no differences between two plasma amino acid levels which were obtained by EDTA and acid citrate (p>0.05). Serum aspartate (asp), glutamate (glu), serine (ser), histidine (his) and phenylalanine (phe) levels were significantly higher in serum than plasma (p

Kaynakça

  • Brummel-Ziedins KE, Pouliot RL, Mann KG. Thrombin generation: phenotypic quantitation. J Thromb Haemost 2004;2:281-6.
  • Mann KG, Gaffney D, Bovill EG. Molecular biology, bio- chemistry and life-span of plasma coagulation factors, in Beutler E, Lichtman MA, Coller BS, Kipps TJ, (eds): Wil- liams Hematology (ed 5). New York, NY, McGraw-Hill, Inc, 1995, p 1206
  • Tracy PB, Eide LL, Mann KG. Human prothrombinase com- plex assembly and function on isolated peripheral blood populations. J Biol Chem 1985;260:2119-23.
  • Davie EW, Fujikawa K, Kisiel W. The coagulation cas- cade: Initiation, maintenance and regulation. Biochemistry 1991;30:1036-9.
  • Rapaport SI, Rao LVM. The tissue factor pathway: How it has become a ”prima ballerina”. Thromb Haemost 1995;4:7-8.
  • Madison EL, Kobe A, Gething MJ, Sambrook JF, Goldsmith EJ. Converting tissue plasminogen activator to a zymogen: a regulatory triad of Asp-His-Ser. Science. 1993;262:419- 21.
  • Scriver C, Kaufman S, Eisensmith R, Woo S. The hyperphe- nylalaninemias. In: Scriver C, Beaudet A, Sly W, Valle D, eds. The metabolic and molecular bases of inherited dis- ease, 8th ed. New York: McGraw-Hill, 2000:1775– 875.
  • Mann KG, Butenas S, Brummel KE. Arterioscler Thromb. Vasc Biol 2003;23:17–25.
  • Ekici OD, Paetzel M, Dalbey RE. Unconventional serine proteases: variations on the catalytic Ser/His/Asp triad con- figuration Protein Sci. 2008;17:2023-37.
  • Mann KG, Kalafatis M. Factor V: a combination of Dr Je- kyll and Mr Hyde. Blood 2003;101:20-30.
  • Kalafatis M. Identification and partial characterization of factor Va heavy chain-kinase from human platelets. J Biol Chem 1998;273:8459-8466.
  • Beblo S, Reinhardt H, Muntau AC, Mueller-Felber W, Ro- scher AA, Koletzko B. Fish oil supplementation improves visual evoked potentials in children with phenylketonuria. Neurology 2001;57:1488-91.
  • Page MJ, Macgillivray RT, Di Cera E. Determinants of specificity in coagulation proteases. J Thromb Haemost 2005;3:2401-8.
  • Dang QD, Di Cera E. Residue 225 determines the Na (+)-in- duced allosteric regulation of catalytic activity in serine proteases. Proc Natl Acad Sci USA 1996; 93: 10653–6.
  • Dang OD, Vindigni A, Di Cera E. An allosteric switch con- trols the procoagulant and anticoagulant activities of throm- bin. Proc Natl Acad Sci USA 1995;92:5977–81.
  • Ruttmann TG, James MFM, Viljoen JF. Haemodilu- tion induces a hypercoagulable state, Brit J Anaesthesia 1996;76:412-414.

İnvitro pıhtılaşmaya farklı bir bakış açısı

Yıl 2010, Cilt: 1 Sayı: 3, 173 - 176, 01.09.2010
https://doi.org/10.5799/ahinjs.01.2010.03.0036

Öz

Amaç: Koagülasyon bilindiği üzere bir dizi zimojenin aktivasyon serisinden oluşur. Her basamakta öncül molekül bir veya daha fazla peptit bağının kopmasıyla aktif proteaza dönüşür. Bu çalışmanın amacı in vitro farklı durumlarda pıhtılaşma sırasında amino asit profilini araştırmaktır. Yöntem: Sağlıklı yetişkinlerden ve fenilketonürili çocuklardan alınan örnekler serum, ETA\'lı plazma ve sitratlı plazma olarak ayrıldı. Örneklerin aminoasit analizleri ters faz HPLC kolonuyla yapıldı. Bulgular: EDTA\'lı ve sitratlı plazmalar arasında anlamlı bir fark görülmedi (p>0.05). Serum aspartat (asp), glutamate (glu), serin (ser), histidin (his) ve fenilalanin (phe) seviyelerinde plazmaya göre anlamlı bir artış kaydedildi (p

Kaynakça

  • Brummel-Ziedins KE, Pouliot RL, Mann KG. Thrombin generation: phenotypic quantitation. J Thromb Haemost 2004;2:281-6.
  • Mann KG, Gaffney D, Bovill EG. Molecular biology, bio- chemistry and life-span of plasma coagulation factors, in Beutler E, Lichtman MA, Coller BS, Kipps TJ, (eds): Wil- liams Hematology (ed 5). New York, NY, McGraw-Hill, Inc, 1995, p 1206
  • Tracy PB, Eide LL, Mann KG. Human prothrombinase com- plex assembly and function on isolated peripheral blood populations. J Biol Chem 1985;260:2119-23.
  • Davie EW, Fujikawa K, Kisiel W. The coagulation cas- cade: Initiation, maintenance and regulation. Biochemistry 1991;30:1036-9.
  • Rapaport SI, Rao LVM. The tissue factor pathway: How it has become a ”prima ballerina”. Thromb Haemost 1995;4:7-8.
  • Madison EL, Kobe A, Gething MJ, Sambrook JF, Goldsmith EJ. Converting tissue plasminogen activator to a zymogen: a regulatory triad of Asp-His-Ser. Science. 1993;262:419- 21.
  • Scriver C, Kaufman S, Eisensmith R, Woo S. The hyperphe- nylalaninemias. In: Scriver C, Beaudet A, Sly W, Valle D, eds. The metabolic and molecular bases of inherited dis- ease, 8th ed. New York: McGraw-Hill, 2000:1775– 875.
  • Mann KG, Butenas S, Brummel KE. Arterioscler Thromb. Vasc Biol 2003;23:17–25.
  • Ekici OD, Paetzel M, Dalbey RE. Unconventional serine proteases: variations on the catalytic Ser/His/Asp triad con- figuration Protein Sci. 2008;17:2023-37.
  • Mann KG, Kalafatis M. Factor V: a combination of Dr Je- kyll and Mr Hyde. Blood 2003;101:20-30.
  • Kalafatis M. Identification and partial characterization of factor Va heavy chain-kinase from human platelets. J Biol Chem 1998;273:8459-8466.
  • Beblo S, Reinhardt H, Muntau AC, Mueller-Felber W, Ro- scher AA, Koletzko B. Fish oil supplementation improves visual evoked potentials in children with phenylketonuria. Neurology 2001;57:1488-91.
  • Page MJ, Macgillivray RT, Di Cera E. Determinants of specificity in coagulation proteases. J Thromb Haemost 2005;3:2401-8.
  • Dang QD, Di Cera E. Residue 225 determines the Na (+)-in- duced allosteric regulation of catalytic activity in serine proteases. Proc Natl Acad Sci USA 1996; 93: 10653–6.
  • Dang OD, Vindigni A, Di Cera E. An allosteric switch con- trols the procoagulant and anticoagulant activities of throm- bin. Proc Natl Acad Sci USA 1995;92:5977–81.
  • Ruttmann TG, James MFM, Viljoen JF. Haemodilu- tion induces a hypercoagulable state, Brit J Anaesthesia 1996;76:412-414.
Toplam 16 adet kaynakça vardır.

Ayrıntılar

Birincil Dil Türkçe
Bölüm Araştırma Yazısı
Yazarlar

Osman Evliyaoğlu Bu kişi benim

Selvi Kelekçi Bu kişi benim

M. Kemal Başaralı Bu kişi benim

Birgül Işık Bu kişi benim

Beri Hocaoğlu Bozarslan Bu kişi benim

Hanım Karahan Bu kişi benim

Yayımlanma Tarihi 1 Eylül 2010
Yayımlandığı Sayı Yıl 2010 Cilt: 1 Sayı: 3

Kaynak Göster

APA Evliyaoğlu, O., Kelekçi, S., Başaralı, M. K., Işık, B., vd. (2010). İnvitro pıhtılaşmaya farklı bir bakış açısı. Journal of Clinical and Experimental Investigations, 1(3), 173-176. https://doi.org/10.5799/ahinjs.01.2010.03.0036
AMA Evliyaoğlu O, Kelekçi S, Başaralı MK, Işık B, Bozarslan BH, Karahan H. İnvitro pıhtılaşmaya farklı bir bakış açısı. J Clin Exp Invest. Eylül 2010;1(3):173-176. doi:10.5799/ahinjs.01.2010.03.0036
Chicago Evliyaoğlu, Osman, Selvi Kelekçi, M. Kemal Başaralı, Birgül Işık, Beri Hocaoğlu Bozarslan, ve Hanım Karahan. “İnvitro pıhtılaşmaya Farklı Bir bakış açısı”. Journal of Clinical and Experimental Investigations 1, sy. 3 (Eylül 2010): 173-76. https://doi.org/10.5799/ahinjs.01.2010.03.0036.
EndNote Evliyaoğlu O, Kelekçi S, Başaralı MK, Işık B, Bozarslan BH, Karahan H (01 Eylül 2010) İnvitro pıhtılaşmaya farklı bir bakış açısı. Journal of Clinical and Experimental Investigations 1 3 173–176.
IEEE O. Evliyaoğlu, S. Kelekçi, M. K. Başaralı, B. Işık, B. H. Bozarslan, ve H. Karahan, “İnvitro pıhtılaşmaya farklı bir bakış açısı”, J Clin Exp Invest, c. 1, sy. 3, ss. 173–176, 2010, doi: 10.5799/ahinjs.01.2010.03.0036.
ISNAD Evliyaoğlu, Osman vd. “İnvitro pıhtılaşmaya Farklı Bir bakış açısı”. Journal of Clinical and Experimental Investigations 1/3 (Eylül 2010), 173-176. https://doi.org/10.5799/ahinjs.01.2010.03.0036.
JAMA Evliyaoğlu O, Kelekçi S, Başaralı MK, Işık B, Bozarslan BH, Karahan H. İnvitro pıhtılaşmaya farklı bir bakış açısı. J Clin Exp Invest. 2010;1:173–176.
MLA Evliyaoğlu, Osman vd. “İnvitro pıhtılaşmaya Farklı Bir bakış açısı”. Journal of Clinical and Experimental Investigations, c. 1, sy. 3, 2010, ss. 173-6, doi:10.5799/ahinjs.01.2010.03.0036.
Vancouver Evliyaoğlu O, Kelekçi S, Başaralı MK, Işık B, Bozarslan BH, Karahan H. İnvitro pıhtılaşmaya farklı bir bakış açısı. J Clin Exp Invest. 2010;1(3):173-6.